Login to Your Account

Series B $63M to 'Relay' disruption in imaging research ways?

By Randy Osborne
Staff Writer

Thursday, December 14, 2017

Sitting “right in the center” of intensified computing power and new experimental methods lets Relay Therapeutics Inc. pursue its method of “bouncing between the virtual and physical world constantly,” CEO Sanjiv Patel told BioWorld, and could mean a powerful change in how drugs are developed, in cancer and beyond.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription